ICU Medical

Vivek Jain serves as Chairman and CEO, overseeing corporate strategy and capital allocation. CFO Brian Bonney and the executive team manage balance sheet decisions. The company is publicly traded, so strategic investments — including M&A and R&D spending — are approved by the board and disclosed in quarterly filings (per the firm's official communications).

ICU Medical is a publicly traded medical device manufacturer, not a family office or venture firm. Its capital is deployed into R&D, manufacturing capacity, and occasional acquisitions — not into external fund vehicles or co-investments. The firm reports financials quarterly to the SEC.

ICU Medical's investment focus is internal: R&D for new infusion systems, disposables, and connectivity software. The firm occasionally acquires complementary technologies or manufacturing capabilities, such as the 2017 Hospira infusion systems acquisition. It does not invest in startups or external funds as a core activity.

As a public company, ICU Medical evaluates potential acquisitions through industry partnerships, hospital feedback, and regulatory trends. Deal flow comes from hospital supply chain relationships, FDA clearance processes, and competitive landscape analysis. The firm does not operate a separate investment sourcing team.

ICU Medical focuses exclusively on infusion therapy and hospital-connected care technologies. It explicitly avoids primary care devices, diagnostic imaging, pharmaceuticals, and consumer health products. The firm's specificity is a strategic choice — it concentrates resources on one clinical workflow across every hospital market.